CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2020—Genentech announced positive data from the phase three IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced nonsquamous and squamous non-small cell lung cancer without ALK or EGFR mutations. The study met its primary endpoint in an interim analysis showing that Tecentriq monotherapy demonstrated a statistically significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy alone. The study will continue to final analysis for people with lower levels of PD-L1 expression.
In a separate release, the company announced that the phase three IMvigor130 study met its co-primary endpoint of investigator-assessed, progression-free survival. Tecentriq plus platinum-based chemotherapy showed a statistically significant reduction in the risk of disease worsening or death in people with previously untreated locally advanced or metastatic urothelial carcinoma compared with chemotherapy alone. Encouraging overall survival results were observed, the company reports; however, these data are not yet mature and follow-up will continue until the next planned analysis.